Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid st...

Descripción completa

Detalles Bibliográficos
Autores: Torres, Armando|||0000-0003-1121-5173, Hernández, Domingo, Moreso, Francesc|||0000-0002-7267-3963, Seron, Daniel|||0000-0003-2054-653X, Burgos, María Dolores, Pallardó, Luis M., Kanter, Julia, Díaz-Corte, Carmen, Rodríguez, Minerva, Díaz Gómez, Juan Manuel|||0000-0002-5653-6619, Silva, Irene|||0000-0002-2723-1031, Valdes, Francisco, Fernández-Rivera, Constantino, Osuna, Antonio, Gracia Guindo, María C., Gómez Alamillo, Carlos, Ruiz, Juan C., Marrero Miranda, Domingo, Pérez-Tamajón, Lourdes, Rodríguez, Aurelio, González-Rinne, Ana, Alvarez, Alejandra, Perez-Carreño, Estefanía, de la Vega Prieto, María José, Henriquez, Fernando, Gallego Samper, Roberto, Salido, Eduardo, Porrini, Esteban
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:211387
Acceso en línea:https://ddd.uab.cat/record/211387
https://dx.doi.org/urn:doi:10.1016/j.ekir.2018.07.009
Access Level:acceso abierto
Palabra clave:Cyclosporin A
Posttransplant diabetes
Posttransplant hyperglycemia
Renal transplantation
Steroid withdrawal
Tacrolimus
Descripción
Sumario:Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was defined by age.

Similares en LA Referencia